ERLONAT (Erlotinib) Tablets are indicated for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR-activating mutations. ERLONAT (Erlotinib) Tablets are also indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC. ERLONAT (Erlotinib) Tablets is also indicated for the treatment of patients with locally advanced or metastatic NSCLC. When prescribing ERLONAT (Erlotinib) Tablets, factors associated with prolonged survival should be taken into account.
Erlonat (Erlotinib) tablets is manufactured by Natco Pharma.
Erlonat (Erlotinib) tablets is available in a bottle of 30 tablets
Erlonat (Erlotinib) is a Kinase inhibitor which is primarily used to treat cell lung cancer, or pancreatic cancer when combined with a certain other medicine. It works by inhibiting growth to adjacent tissues in the body so that the cancerous cells slow down, allowing the patient a better environment to recover and fight the cancer naturally.
Avalon Pharma is an exporter of Erlonat (Erlotinib) tablets and a supplier of Erlonat (Erlotinib) tablets